Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
Dimo DietrichSimone WeiderLuka de VosTimo Jakob VogtMoritz FärberRomina ZarblAlina HuneckeAnn-Kathrin GloschJennis GabrielpillaiFriedrich BootzFranz-Georg BauernfeindFranz-Josef KramerGlen KristiansenPeter BrossartSebastian StriethAlina FranzenPublished in: Clinical chemistry (2023)
Post-surgical SEPT9 ccfDNA methylation may aid to identify high-risk HNSCC patients who could benefit from an intensified adjuvant treatment and surveillance.